Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 3 art units • 5 examiners • 0 of 6 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Adama Agan Ltd. maintains an active patent portfolio in the Biotechnology & Pharmaceuticals technology area with 7 pending office actions. This workload is distributed across 6 distinct examiners, indicating a broad engagement with USPTO personnel. The company's prosecution efforts span 4 distinct art units, reflecting a range of technical classifications within the life sciences sector.
PAK, JOHN D is the busiest examiner for the portfolio, currently managing 2 pending office actions. While most examiners are handling single matters, PAK, JOHN D has a slightly higher concentration of the company's 7 pending office actions. This distribution across 6 distinct examiners helps the company avoid excessive reliance on any single individual's perspective.
The involvement of 4 distinct art units suggests that the company's research and development efforts are diversified. PAK, JOHN D, with 2 pending office actions, is the only examiner handling more than one matter. This level of activity in Biotechnology & Pharmaceuticals reflects a robust approach to securing patent protection for their agricultural and chemical innovations.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (17%) |
| §103 only | 4 (67%) |
| Multi-statute (no §101) | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PAK, JOHN D | 2 | 52.3% | +37.8% |
| WAX, ROBERT A | 1 | 25.7% | +3.9% |
| ZHANG SPIERING, DONGXIU | 1 | 41.2% | +65.2% |
| WORSHAM, JESSICA N | 1 | 56.6% | +56.4% |
| HIRT, ERIN E | 1 | 40.6% | +22.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18877889 | METHOD OF APPLICATION OF HERBICIDAL ACTIVE INGREDIENTS IN DIFFERENT STAGES | WAX, ROBERT A | — |
| 18719973 | STABLE SUSPOEMULSIONS | PAK, JOHN D | — |
| 18547527 | HERBICIDAL COMPOSITIONS COMPRISING IMIDAZOLINONE-BASED ACETOLACTATE SYNTHASE INHIBITORS AND USES THEREOF | PAK, JOHN D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18560244 | STABLE AGROCHEMICAL SUSPENSION CONCENTRATE COMPOSITIONS | ZHANG SPIERING, DONGXIU | 73d overdue |
| 18719973 | STABLE SUSPOEMULSIONS | PAK, JOHN D | — |
| 18280120 | SOLID FORMS OF SAFLUFENACIL-SODIUM AND SAFLUFENACIL-POTASSIUM, PROCESS OF PREPARATION AND USE THEREOF | WORSHAM, JESSICA N | — |
| 18547527 | HERBICIDAL COMPOSITIONS COMPRISING IMIDAZOLINONE-BASED ACETOLACTATE SYNTHASE INHIBITORS AND USES THEREOF | PAK, JOHN D | — |
| 17792306 | Solid State Form of Pyroxasulfone | HIRT, ERIN E | — |
| Art Unit | Apps |
|---|---|
| 1615 | 2 |
| 1699 | 2 |
| 1616 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18877889 | METHOD OF APPLICATION OF HERBICIDAL ACTIVE INGREDIENTS IN DIFFERENT STAGES | WAX, ROBERT A | 1615 | §103 | Non-Final OA | — | Pending | Dec 20, 2024 |
| 18719973 | STABLE SUSPOEMULSIONS | PAK, JOHN D | 1699 | §101§103§112DP | Non-Final OA | — | Pending | Jun 14, 2024 |
| 18560244 | STABLE AGROCHEMICAL SUSPENSION CONCENTRATE COMPOSITIONS | ZHANG SPIERING, DONGXIU | 1616 | §103 | Final Rejection | 73d overdue | Pending | Nov 10, 2023 |
| 18280120 | SOLID FORMS OF SAFLUFENACIL-SODIUM AND SAFLUFENACIL-POTASSIUM, PROCESS OF PREPARATION AND USE THEREOF | WORSHAM, JESSICA N | 1615 | §103 | Final Rejection | — | Pending | Sep 01, 2023 |
| 18547527 | HERBICIDAL COMPOSITIONS COMPRISING IMIDAZOLINONE-BASED ACETOLACTATE SYNTHASE INHIBITORS AND USES THEREOF | PAK, JOHN D | 1699 | §102§103 | Final Rejection | — | Pending | Aug 23, 2023 |
| 17792306 | Solid State Form of Pyroxasulfone | HIRT, ERIN E | 1616 | §103 | Final Rejection | — | Pending | Jul 12, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAdama Agan Ltd. has 6 pending office actions as of October 2026, spread across 3 art units and 5 examiners.
John D Pak has the most, with 2 of Adama Agan Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
